New hope for hard-to-treat lymphoma: drug combo targets relapsed cases
NCT ID NCT07279584
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 18 times
Summary
This study tests whether a new drug called golidocitinib, when combined with standard chemotherapy (GemOx), can shrink tumors in people whose peripheral T-cell lymphoma has returned or stopped responding to treatment. About 31 adults will receive the combination and be monitored for safety and how well it works. The goal is to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMAS (PTCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.